M. Elisabeth· @ChildrenNeedUs_ · X·· 2026-04-19Score60
Reading
KRAS / RAS targeting: from platform to Phase 3
daraxonrasib ± GnP · mono ORR 47%; +GnP ORR 55%, DCR 90%
Body
Another win for patients with pancreatic cancer.
This project began 5+ years ago by Genentech & BioNtech— human trials began 2020 before the full force of propaganda against mRNA took hold.
#AACR26
#AACR2026
#PancreaticCancer
Heat 12 · 9 likes · 1 reply · 2 reposts
Source: M. Elisabeth · x.com